Latest FDA product-specific guidelines – Some questions… [Regulatives / Guidelines]

posted by Achievwin – US, 2017-07-25 19:33 (2438 d 12:49 ago) – Posting: # 17610
Views: 9,853

❝ ❝ Phenotype is not advisable in generic arena (IMHO) as we want to document that this drug is BE in general populating (meaning any breathing soul)....


❝ EMA allows. See Jun 2017 by Laszlos and H- Blume on "real life" vs. "highly discriminative" in BE study requirements in various regions. Spoiler: Very inconsistent, in general... ;-)


BE guidance tries to avoid bias (cherry picking) therefore excluded Phenotyping and avoiding fast and slow metabolizers.... if we allow phenotyping then next someone will come and ask for BMI exceptions and then smoker exclusion where is the end?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5 and follow the Forum’s Policy. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
106 visitors (0 registered, 106 guests [including 4 identified bots]).
Forum time: 07:23 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5